Browse > Article

The Changes of Central Aortic Pulse Wave Analysis in Metabolic Syndrome  

Lee, Jee-In (Department of Internal Medicine, The Catholic University of Korea, College of Medicine)
Sohn, Tae-Seo (Department of Internal Medicine, The Catholic University of Korea, College of Medicine)
Kwon, Hyuk-Sang (Department of Internal Medicine, The Catholic University of Korea, College of Medicine)
Lee, Jung-Min (Department of Internal Medicine, The Catholic University of Korea, College of Medicine)
Chang, Sang-Ah (Department of Internal Medicine, The Catholic University of Korea, College of Medicine)
Cha, Bong-Yun (Department of Internal Medicine, The Catholic University of Korea, College of Medicine)
Son, Hyun-Shik (Department of Internal Medicine, The Catholic University of Korea, College of Medicine)
Publication Information
Diabetes and Metabolism Journal / v.32, no.6, 2008 , pp. 522-528 More about this Journal
Abstract
The metabolic syndrome (MS) has been characterized as a cluster of risk factors that includes dyslipidemia, hypertension, glucose intolerance and central obesity. This syndrome increases the risk of cardiovascular disease. Augmentation index (AIx), a composite of wave reflection form medium-sized muscular arteries is related to the development of coronary artery disease. The aim of this study is to examine the change on central aortic waveforms in subjects between patients with metabolic syndrome and normal subjects. Using the non-invasive technique of pulse wave analysis by applantation tonometry, we investigated central aortic waveforms in 45 patients with MS and 45 matched controls. The MS was defined by NCEP-ATP III criteria. Age did not differ between the two groups. AIx was significantly elevated in patinets with MS compared with controls (21.91 ± 11.41% vs 18.14 ± 11.07%; P < 0.01). Subendocardial viability ratio (SEVR) (158.09 ± 28.69 vs 167.09 ± 30.06; P < 0.01) was significantly decreased in patients with MS compared with controls. Only the fasting glucose (r = 0.317, P = 0.03) among the components of MS and age (r = 0.424, P = 0.004) had a positive correlation with AIx. AIx increased as the number of MS components increased. These results show that the MS increased systemic arterial stiffness. Age and fasting blood glucose are independent risk factors of arterial stiffness in MS. The individual MS components, except for fasting blood glucose, do not affect arterial stiffness independently. But the clustering of MS components might interact to synergistically affect arterial stiffness. (KOREAN DIABETES J 32:522-528, 2008)
Keywords
Arterial stiffness; Augmentation index; Metabolic syndrome; Pulse wave analysis
Citations & Related Records
연도 인용수 순위
  • Reference
1 Grundy SM: A constellation of complications: the metabolic syndrome. Clin Cornerstone. 7:36-45, 2005   DOI   ScienceOn
2 Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-44, 1993   DOI   ScienceOn
3 K ylin E , S tudien: H ypertonie-hyperg lykam iehyperurikamie syndrome. Zentralblatt fur innere medizin 44:105-27, 1923
4 Vageu J: La differenciation sexuelle. facteur determinant des formes de l'obesite. Press Med. 30:339-40, 1947
5 Lakka HM, Laaksonen DE, Lakka TA: The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 288:2709-16, 2002   DOI   ScienceOn
6 Ferro G, Diulio C, Spinelli L: Relation between diastolic perfusion time and coronary artery stenosis during stress-induced myocardial ischaemia. Circulation 92:342-47, 1995   DOI   ScienceOn
7 O'Rourke MF, Seward JB: Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov. Mayo Clin Proc 81:1057-68, 2006
8 London GM, Asmar RG, O'Rourke MF, Safar ME: REASON project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Caridol 43:92-9, 2004   DOI   ScienceOn
9 Nichols WW, O'Rourke MF: Mcdonald's blood flow in arteries. Theoretical, experimental and clinical principles. 4th ed. London, Arnold, 1998
10 Malik S, Wong ND, Franklin SS: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110:1245-50, 2004   DOI   ScienceOn
11 Robert H Eckel, Scott M Grundy, Paul Z Zimmet: The metabolic syndrome. The Lancet 365:1415-28, 2005   DOI   ScienceOn
12 O'Rourke MF, Kelly RP, Avolio AP: The arterial pulse. Lea & Febiger, London, 1992
13 Hirata K, Kawakami M, O'Rourke MF: Pulse wave analysis and pulse wave velocity: a review of blood pressure interpretation 100 years after Korotkov. Circ J 70:1231-9, 2006   DOI   ScienceOn
14 Girman CJ, Rhodes T, Mercuri M: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93:136-41, 2004   DOI   ScienceOn
15 강자영, 최현아, 윤홍선, 유성훈, 송민준, 장유진, 김헌 성, 신현호, 박정배, 이원로: 본태성 고혈압 환자에서 안 지오텐신 수용체 차단제 irbesartan에 의한 혈관 경직도 의 개선. 대한내과학회지 67:241-48, 2004
16 Buckberg GD, Towers B, Paglia DE: Experimental subendocardial ischaemia in dogs with normal coronary arteries. Circ Res 30:67-81, 1972   DOI   ScienceOn
17 Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA: Clinical management of metabolic syndrome: Report of the American Heart Association/ National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109:551-6, 2004   DOI   ScienceOn
18 Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart study. Circulation 103:1245-9, 2001   DOI   ScienceOn
19 Oliver JJ, Webb DJ: Noninvasive assessment of arterial stiffenss and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 23:554-66, 2003   DOI   ScienceOn
20 Reaven GM, Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 37:1595-607, 1988   DOI   ScienceOn
21 Kannel WB, Gordon T, Schwartz MJ: Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham study. Am J Cardiol 27:335-46, 1971   DOI   ScienceOn
22 Wlliams B, Lacy PS, Thom SM: CAFE investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, Cafe Stering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes; principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213-25, 2006   DOI   ScienceOn
23 Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-97, 2001   DOI   ScienceOn
24 Hanley AJ, Karter AJ, Williams K, Festa A, D'Agostino RB Jr, Wagenknecht LE, Haffner SM: Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 112: 3713-21, 2005   DOI   ScienceOn
25 Zieman SJ, Melenovsky V, Dass DA: Mechanisms, pathophysiology, and therapy of arterial stiffness. Arteriscler Thromb Vasc Biol 932-43, 2005
26 Nichols WW: Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. AJH 18:3S-10S, 2005